Here's where traders could go long.
The maker of robotic products for minimally invasive surgery looks like a long play based on its technical signals.
Here's how traders can play it.
It will take more than the company's potential talc litigation settlement to reverse the stock's downward path the past 12 months.
BSX has rallied the past nine months.
Trying to catch this drug developer's stock appears risky.
Here's what I think we'll see up ahead.
Keep this stock on your watch list.
Here's what to avoid for now.
Let's check out the charts and indicators of both NovoCure and Zai Lab.